Anika Therapeutics Completes Enrollment in MONOVISC Pivotal U.S. Clinical Trial
"Completing the enrollment of the U.S. trial for MONOVISC brings us closer to the domestic commercialization of our single-injection osteoarthritis product," said Charles H. Sherwood, Ph.D., Anika's president and chief executive officer. "MONOVISC is being very well received in Europe, where we launched the product in May. Coincident with that launch, we completed a post-approval study of MONOVISC in Europe and the interim results on the product's performance and duration of action are very strong."
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.